Amyloid β, Tau, and α-Synuclein Aggregates in the Pathogenesis, Prognosis, and Therapeutics for Neurodegenerative Diseases

Dear Colleagues,

Alzheimer’s disease (AD) is characterized by the progressive and irreversible decline of memory, thinking and cognitive abilities, and is the most common form of neurodegenerative dementia. More than 55 million people suffer from dementia worldwide, and the patient number is anticipated to rise to 139 million by 2050 because of population ageing. Presently, AD remains incurable, and the high failure rate of clinical trials for AD-related drugs have raised the need to understand the symptoms of AD. Worst of all, its underlying etiology is still not well understood. Therefore, AD has posed tremendous challenges for both scientific researchers and medical experts to tackle the unresolved issues in early detection, diagnostics and therapeutics for AD. The use of advanced technology for the treatment of AD in diagnostics, brain delivery, and therapeutics will help to yield solutions from bench to bedside in AD therapy.

This Research Topic welcomes contributions, in the form of original research articles or reviews and opinions, to address/summarize the challenges and understanding of Amyloid β, Tau, and α-Synuclein Aggregates in the Pathogenesis, Prognosis, and Therapeutics for Neurodegenerative Diseases.

Dr. Ashok Iyaswamy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.